

Targeting Biofilms with Nanoparticles: Mechanisms and Clinical Implications

Maqsood Ahmed* and Hassan Butt

Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Sindh, Pakistan

Abstract

Biofilm-associated infections represent one of the greatest challenges in modern medicine due to their inherent resistance to antibiotics and host immune responses. The dense extracellular polymeric substance (EPS) and altered bacterial physiology within biofilms make treatment extremely difficult, contributing to chronic and recurrent infections in clinical settings. Nanoparticles have emerged as promising therapeutic agents because of their unique physicochemical properties, enhanced surface reactivity, and ability to penetrate biofilm matrices. This review summarizes the structural complexity of biofilms, the limitations of conventional antimicrobial therapies, and the mechanisms by which nanoparticles exert anti-biofilm actions. It further discusses the types of nanoparticles explored, current clinical applications, safety considerations, and future prospects for integrating nanotechnology into routine clinical management of biofilm-associated infections.

Key Words: Biofilms, Nanoparticles, Clinical Implications

*Address of Correspondence: Email: maqsoodahmedshaikh5454@gmail.com

Submitted on 26-12-2025– Revised on 30-12-2025– Accepted on 31-12-2025 Published on 5-1-26

INTRODUCTION

Biofilms are highly organized microbial communities embedded in a self-produced extracellular polymeric matrix composed of polysaccharides, proteins, extracellular DNA, and lipids. Unlike planktonic (free-floating) bacteria, biofilm-embedded microorganisms exhibit altered gene expression, increased tolerance to antimicrobials, and enhanced survival under hostile conditions (Ugwu et al., 2025). Biofilms are prevalent in a wide range of clinical environments, particularly involving chronic wounds, dental plaques, orthopedic implants, catheters, prosthetic devices, and respiratory infections such as those seen in cystic fibrosis (Sattar et al.,

2025; Thakre, Bankar, Tiwade, & Mishra, 2025).

Conventional antibiotic therapy is often inadequate because antimicrobial agents exhibit poor penetration through the EPS matrix and reduced efficacy against metabolically dormant bacterial subpopulations. Consequently, persistent infections, treatment failure, and increased healthcare costs remain major clinical burdens (Khadim et al., 2024). Nanotechnology has emerged as a transformative strategy in biomedical science, offering novel antimicrobial platforms with improved delivery efficiency, enhanced interaction with microbial cells, and the capability to

combat antibiotic resistance. This review provides a comprehensive overview of nanoparticle-mediated strategies targeting biofilms and explores their translational potential in clinical practice(Rehman, Ahmed, Hashmi, & Jamil, 2017).

Biofilms and Their Clinical Significance

Biofilm formation is a dynamic, multi-step process involving initial attachment, microcolony formation, maturation, and eventual dispersal(Patil, 2025). Once established, biofilms pose serious clinical consequences. Approximately 65–80% of human microbial infections are biofilm-associated. Biofilms on indwelling medical devices such as urinary catheters, central venous lines, prosthetic heart valves, and orthopedic implants frequently lead to persistent device-related infections(Khardori & Yassien, 1995). In chronic wounds, biofilms delay healing, stimulate inflammation, and contribute to recurrent infections. In pulmonary diseases, particularly cystic fibrosis, *Pseudomonas aeruginosa* biofilms are difficult to eradicate and associated with poor prognosis(Shakeel, Iffat, Qamar, Nesar, et al., 2022).

Challenges in Treating Biofilm-Associated Infections

Multiple factors contribute to the resilience of biofilms:

1.Physical Barrier: The EPS matrix acts as a diffusion barrier, limiting antimicrobial penetration.

2.Altered Bacterial Physiology: Bacteria within deeper layers enter a slow-growing or dormant state, reducing susceptibility to antibiotics that target active metabolism(Shakeel, Iffat, Qamar, Rehman, et al., 2022).

3.Efflux Pumps and Genetic Adaptation:


Biofilms facilitate horizontal gene transfer, enhancing antimicrobial resistance(Rehman, Jamil, Owais, Naveed, & Usmanghani, 2017).

4.Quorum Sensing: Cell-to-cell communication systems regulate virulence and biofilm stability.

5.Immune Evasion: Biofilms impair phagocyte access and protect bacteria from immune clearance.

Due to these mechanisms, conventional antibiotic therapy often requires prolonged treatment, combination regimens, or surgical removal of infected devices, highlighting the need for innovative solutions.

Mechanisms of Nanoparticle Action Against Biofilms



1: Nanoparticles as Anti-Biofilm Agents

Nanoparticles are ultrafine materials (1–100 nm) possessing unique properties such as high surface-to-volume ratio, tunable surface chemistry, and enhanced reactivity. These characteristics enable nanoparticles to penetrate biofilms, disrupt microbial structures, and deliver antimicrobial agents more efficiently. Their versatility allows engineering for targeted delivery, controlled release, and synergistic

interactions with conventional Anti-Biofilm(Li et al., 2024).

2: Physical Disruption of Biofilm Structure

Due to their nanoscale dimensions, nanoparticles can infiltrate the EPS matrix and destabilize its architecture. Some nanoparticles adhere to biofilm surfaces, altering permeability and mechanical integrity, ultimately leading to biofilm detachment or collapse.

3: Chemical Interactions and Reactive Oxygen Species (ROS) Generation

Metal-based nanoparticles such as silver (AgNPs), zinc oxide (ZnO), and titanium dioxide (TiO₂) generate reactive oxygen species, including hydroxyl radicals, singlet oxygen, and superoxide ions. These induce oxidative stress, damage microbial membranes, denature proteins, and disrupt nucleic acids(Rehman, Ali, Naveed, & Usmanhane, 2017).

4: Release of Metal Ions

Certain nanoparticles release antimicrobial ions (Ag⁺, Cu²⁺, Zn²⁺) that interact with bacterial cell walls, inhibit enzyme activity, interfere with DNA replication, and alter metabolic pathways(Rehman, Shaikh, Naveed, Latif, & Usmanhane, 2016).

5: Membrane Interaction and Damage

Nanoparticles can directly interact with bacterial cell membranes, altering membrane potential, increasing permeability, and causing cell lysis.

6: Drug Delivery and Controlled Release

Nanoparticles serve as carriers for antibiotics, peptides, or antiseptics. Encapsulation protects drugs from degradation, enhances localized

concentration within the biofilm, and allows sustained release. This improves therapeutic efficiency while reducing systemic toxicity.

7: Interference with Quorum Sensing

Functionalized nanoparticles can inhibit quorum-sensing pathways, preventing bacterial communication and reducing virulence, adhesion, and biofilm maturation.

Types of Nanoparticles Used Against Biofilms

1: Metallic Nanoparticles

Silver, gold, copper, and zinc oxide nanoparticles are extensively studied due to their strong intrinsic antimicrobial properties. Silver nanoparticles, in particular, show broad-spectrum antibacterial activity and effective biofilm penetration(Sadia, Naveed, Rehman, & Jamshed, 2025; Sadia, Naveed, Rehman, Jamshed, & Dilshad, 2025).

2: Polymeric Nanoparticles

Biodegradable polymers such as chitosan, PLGA, and PEG-based nanoparticles offer biocompatibility, controlled drug release, and targeting abilities. Chitosan possesses inherent antimicrobial and bioadhesive properties(Qamar, Sana, Naveed, & Faizi, 2023).

3: Lipid-Based Nanoparticles

Liposomes and solid lipid nanoparticles improve antibiotic delivery, enhance cellular uptake, and reduce toxicity(Kaleem et al., 2025).

4: Magnetic Nanoparticles

Magnetic nanoparticles enable externally controlled targeting and stimulus-responsive drug delivery. They can disrupt biofilms mechanically under applied magnetic fields.

5: Carbon-Based Nanomaterials

Graphene oxide, carbon nanotubes, and fullerenes exhibit strong antimicrobial actions through membrane disruption, oxidative stress, and physical cutting effects.

Clinical Applications

Nanoparticle-based strategies are being explored or implemented in several clinical areas:

Wound Healing: Nanoparticle-containing dressings demonstrate enhanced antibacterial activity and improved healing outcomes(Farooqi et al., 2024; Siddiqui & Naveed, 2025).

Dental Applications: Nanoparticles are incorporated in toothpaste, dental composites, and mouth rinses to prevent plaque formation.

Implant and Device Coatings: Antimicrobial nanoparticle coatings reduce colonization on catheters, prostheses, and orthopedic implants.

Respiratory Therapy: Inhalable nanoparticle systems show potential for targeting lung biofilms in cystic fibrosis(Khanum et al., 2017).

Orthopedics: Nano-coated implants reduce biofilm formation and improve implant longevity.

Safety Considerations and Limitations

Despite promising results, several challenges remain:

Cytotoxicity: Some nanoparticles may damage host cells, induce oxidative stress, or accumulate in organs.

Biodegradability: Persistence of non-degradable nanoparticles poses long-term risk(Shakeel et al., 2020).

Standardization Issues: Lack of standardized synthesis methods complicates reproducibility.

Regulatory Barriers: Limited clinical trials restrict regulatory approval and widespread clinical use.

Cost and Scalability: Large-scale production remains expensive.

Future Perspectives

Future advancements are expected to focus on:

- 1: Smart stimuli-responsive nanoparticles triggered by pH, enzymes, heat, or light.
- 2: Target-specific functionalization for precision therapy.
- 3: Synergistic combinations of nanoparticles with antibiotics or phage therapy.
- 4: Personalized Nano medicine tailored to infection type and patient profile.
- 5: More clinical trials to validate long-term safety and efficacy.

CONCLUSION

Nanoparticle-based strategies represent a powerful and innovative approach to combating biofilm-associated infections. Their ability to penetrate EPS matrices, disrupt microbial structures, deliver antimicrobial agents effectively, and interfere with quorum sensing provides significant therapeutic advantages.

Although safety concerns and regulatory challenges remain, ongoing advancements in nanotechnology continue to strengthen its potential as a transformative tool in

clinical medicine, paving the way for improved management of persistent and resistant biofilm infections(Almatroudi, 2025).

REFERENCES:

- Almatroudi, A. (2025). Biofilm resilience: Molecular mechanisms driving antibiotic resistance in clinical contexts. *Biology*, 14(2), 165.
- Farooqi, S. S., Naveed, S., Qamar, F., Sana, A., Farooqi, S. H., Sabir, N., . . . Sadia, H. (2024). Phytochemical analysis, GC-MS characterization and antioxidant activity of *Hordeum vulgare* seed extracts. *Heliyon*, 10(6).
- Kaleem, A., Sana, A., Khan, R. U., Naveed, S., Qamar, F., Zainab, S., . . . Sathian, B. (2025). Next-gen ferulic acid-stabilized gold nanoparticles: exploring their sensing capabilities and therapeutic efficacy. *Therapeutic Delivery*, 16(5), 447-457.
- Khadim, S., Muhammad, I. N., Alam, T., Usman, S., Rehman, H., & Haider, S. (2024). Predictors of Successful First-Line *Helicobacter pylori* Eradication with Fluoroquinolones in Pakistan: A Prospective Exploration of Demographic and Clinical Factors. *Antibiotics*, 13(3), 211. Retrieved from <https://www.mdpi.com/2079-6382/13/3/211>
- Khanum, K., Zahoor, A., Ali, R., Usmanghani, K., Rehman, H., Alam, M. O., . . . Naveed, S. (2017). Clinical studies of linkus syrup for efficacy and safety for the treatment of cough, respiratory infection in children. *RADS Journal of Pharmacy and Pharmaceutical Sciences*, 5(2), 36-43.
- Khardori, N., & Yassien, M. (1995). Biofilms in device-related infections. *Journal of industrial microbiology and biotechnology*, 15(3), 141-147.
- Li, H., Yang, Z., Khan, S. A., Walsh, L. J., Seneviratne, C. J., & Ziora, Z. M. (2024). Characteristics of metallic nanoparticles (especially silver nanoparticles) as anti-biofilm agents. *Antibiotics*, 13(9), 819.
- Patil, M. (2025). Biofilm: A Life for Microorganisms with Basic Biofilm Principles.
- Qamar, F., Sana, A., Naveed, S., & Faizi, S. (2023). Phytochemical characterization, antioxidant activity and antihypertensive evaluation of *Ocimum basilicum* L. in l-NAME induced hypertensive rats and its correlation analysis. *Heliyon*, 9(4).
- Rehman, H., Ahmed, Z., Hashmi, F., & Jamil, K. (2017). Challenging status about patient centricity among health care profession in Pakistan. *Rawal Med J*, 42(3), 414-420.
- Rehman, H., Ali, S. A., Naveed, S., & Usmanghani, K. (2017). An interquartile relationship between polyherbal extract based lozenges linkus a phase IV comparative randomised control trial. *Pak. J. Pharm. Sci*, 30(3), 961-966.
- Rehman, H., Jamil, K., Owais, A., Naveed, S., & Usmanghani, K. (2017). ANTIMICROBIAL ANALYSIS OF POLYHERBAL FORMULATION LINKUS COUGH SYRUP.
- Rehman, H., Shaikh, Z. A., Naveed, S., Latif, M., & Usmanghani, K. (2016). Evaluation of in vitro antioxidant, reducing, lipoxxygenase and ACE inhibition activity of polyherbal drug linkus. *African*

- Journal of Pharmacy and Pharmacology*, 10(44), 945-953.
- Sadia, H., Naveed, S., Rehman, H., & Jamshed, S. (2025). To prescribe or not to prescribe in the elderly: a qualitative exploration of prescribing dilemmas among Pakistani healthcare providers. *BMJ open*, 15(4), e094545.
- Sadia, H., Naveed, S., Rehman, H., Jamshed, S., & Dilshad, H. (2025). Enhancing medication appropriateness: Insights from the STOPP (Screening Tool of Older Persons' Prescriptions) criteria version 3 on prescribing practices among the older adults in Pakistan. *Frontiers in Pharmacology*, 16, 1551819.
- Sattar, A., Rehman, H., Naveed, S., Khadim, S., Khan, N., Kazi, A. F., . . . Jamshed, S. (2025). Trustworthiness of Web-Based Pharmacy Apps in Pakistan Based on the Mobile App Rating Scale: Content Analysis and Quality Evaluation. *JMIR mHealth and uHealth*, 13(1), e59884.
- Shakeel, S., Iffat, W., Qamar, A., Nesar, S., Butt, F., Siddiqui, S. N., . . . Rehman, A. u. (2022). Assessment of knowledge, attitude, and practice of obstetricians and gynecologists toward off-label medicine use in female reproductive health issues. *Frontiers in Public Health*, 10, 829339.
- Shakeel, S., Iffat, W., Qamar, A., Rehman, H., Ghuman, F., Butt, F., . . . Gajdács, M. (2022). Healthcare professionals' compliance with the Standard Management Guidelines towards the Use of Biological Disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients. *International journal of environmental research and public health*, 19(8), 4699.
- Shakeel, S., Mohamed, A. H., Rehman, H., Iffat, W., Yasmin, R., & Farrukh, U. (2020). Explanatory findings of prescribing biosimilar medicines in oncology care settings of Pakistan. *Lat. Am. J. Pharm*, 39(10), 2041-2045.
- Siddiqui, U. N., & Naveed, D. (2025). Nature's forgotten emulsifier: revisiting the chemistry, application and use of Gum acacia. *International Journal of Trends in Pharmaceutical and Chemical Research*, 3(1).
- Thakre, R., Bankar, N., Tiwade, Y., & Mishra, V. (2025). The battle against biofilms: understanding the impact on medical devices and patient health. *Reviews and Research in Medical Microbiology*, 36(2), 95-101.
- Ugwu, C. N., Ezeibe, E. N., Emencheta, S. C., Nwagwu, C. S., Ogbonna, K. O., Ejiofor, C. V., . . . Attama, A. A. (2025). Biofilms: structure, resistance mechanism, emerging control strategies, and applications. *RSC Pharmaceutics*.